Secukinumab bests placebo for sustained remission in polymyalgia rheumatica

Secukinumab was superior to placebo in exhibiting sustained remission at 52 weeks in patients with relapsed polymyalgia rheumatica, according to findings published in the New England Journal of Medicine.“Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips,” John H. Stone, MD, of the division of rheumatology,